



THE ROLE OF ARTIFICIAL INTELLIGENCE IN DIABETES CARE AND
MANAGEMENT: A COMPREHENSIVE REVIEW

Komal Kanwar^{*1}, Anil Kumhar¹, Surabhi Raviprakash Singh²

^{*1}Scholars Sri Balaji College of Pharmacy, Jaipur.

²Assistant Professor Sri Balaji College of Pharmacy, Jaipur.



***Corresponding Author: Komal Kanwar**

Scholars Sri Balaji College of Pharmacy, Jaipur.

DOI: <https://doi.org/10.5281/zenodo.22687504>



How to cite this Article: Komal Kanwar¹, Anil Kumhar¹, Surabhi Raviprakash Singh². (2026). The Role of Artificial Intelligence In Diabetes Care and Management: A Comprehensive Review. European Journal of Biomedical and Pharmaceutical Sciences, 13(9), 298–302.

This work is licensed under Creative Commons Attribution 4.0 International license.

Article Received on 15/08/2026

Article Revised on 05/09/2026

Article Published on 10/09/2026

ABSTRACT

Diabetes mellitus represents a global metabolic crisis characterized by complex self-management requirements, marked physiological variability, and significant risks of microvascular and macrovascular complications. The integration of **Artificial Intelligence (AI)**—including Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and Deep Reinforcement Learning (DRL)—is transforming clinical endocrinology from reactive treatment paradigms into proactive, continuous, and highly personalized care models. This review synthesizes current AI methodologies across diabetes care, examining continuous glucose forecasting, closed-loop automated insulin delivery, point-of-care microvascular screening, population-level risk stratification, and behavioral digital health interventions. Furthermore, it addresses critical translational bottlenecks—such as model opacity, demographic algorithmic bias, and regulatory liabilities—and outlines future paradigms in digital health.

KEYWORDS: Artificial intelligence, diabetes mellitus, automated insulin delivery, continuous glucose monitoring, diabetic retinopathy, diabetic foot ulcer, machine learning.

INTRODUCTION

Diabetes management requires continuous daily balancing of insulin delivery, dietary intake, physical exertion, and stress levels. Traditional episodic care based on point-in-time glycated hemoglobin measurements often fails to capture high-frequency glucose oscillations (glycemic variability) that drive long-term microvascular end-organ damage. The exponential growth of Continuous Glucose Monitoring (CGM) sensors, smart connected pens, automated insulin pumps, and health wearables generates continuous streams of multi-modal biosensing data.

Manual synthesis of these vast datasets during routine clinic visits exceeds human analytical capacity. AI serves as the computational engine capable of converting unstructured and continuous biological data into precise, actionable clinical decision-making support.

Advantages of AI in Diabetes Management

The major potential advantages of AI include

1 Early detection

AI may identify high-risk individuals and early disease patterns before conventional clinical recognition.

2 Continuous monitoring

AI can process repeated measurements from CGM and wearable devices and detect clinically relevant trends.

3 Personalized decision support

Models can integrate numerous patient variables to generate individualized predictions.

4 Improved screening

Automated image analysis may expand access to diabetic retinopathy screening.

5 Reduced healthcare workload

AI may automate repetitive analytical tasks and help clinicians prioritize patients requiring attention.

6 Patient engagement

Digital AI tools can provide reminders, educational information and feedback based on patient-generated data.

7 Population-level risk management

Healthcare systems may use predictive models to identify populations requiring preventive interventions.

Limitations and Challenges

Despite its potential, AI has several limitations.

1 Data quality

AI systems are highly dependent on the quality of their training data. Missing, inaccurate or inconsistent information can produce unreliable predictions.

2 Algorithmic bias

If training data do not adequately represent different populations, an AI system may perform less effectively in underrepresented groups.

3 Explainability

Some complex models operate as "black boxes," making it difficult for healthcare professionals to understand why a particular prediction was generated.

4 Privacy

Diabetes-related datasets may contain sensitive clinical, behavioral and physiological information. Appropriate data protection and governance are therefore essential.

5 Cyber security

Connected medical devices create potential cybersecurity vulnerabilities. Unauthorized access or manipulation of medical data or device functionality could have serious consequences.

6 Interoperability

AI systems need to communicate with electronic health records, CGM platforms, laboratory systems and other digital technologies. Lack of interoperability can restrict clinical usefulness.

7 False predictions

An AI model can generate both false-positive and false-negative results. The clinical consequences of such errors must be evaluated carefully.

8 Cost and accessibility

Advanced AI-enabled technologies may be expensive and may not be equally available to all patients.

9 Human–AI interaction

Overreliance on automated recommendations could lead to inappropriate decisions. AI should support professional judgment rather than eliminate it.

Advanced Clinical Applications of AI

1 Predictive Glycemic Analytics and Time-Series Modeling

Standard CGM devices rely on static threshold alarms that trigger only *after* dysglycemic boundaries are breached. AI algorithms alter this model by forecasting glycemic trajectories 30 to 60 minutes in advance.

- **Predictive Hypoglycemia Alarms:** Advanced time-series ML models—such as Long Short-Term Memory (LSTM) networks, Gated Recurrent Units (GRUs), and Gradient Boosting Trees—process sequential glucose trends alongside meal and activity inputs to forecast nocturnal low-glucose episodes
- **Clinical Utility:** Providing 30–60 minute lead times allows individuals to ingest fast-acting

carbohydrates proactively, significantly reducing nocturnal fear and severe hypoglycemic events.

2 Automated Insulin Delivery (AID) & Closed-Loop Systems

In Type 1 Diabetes (T1D), AID platforms connect CGMs directly with subcutaneous insulin pumps.

- **Deep Reinforcement Learning (DRL) Adaptation:** While classical control systems (such as Model Predictive Control) rely on pre-programmed physiological parameters, DRL agents learn optimal dosing policies through continuous environment interaction
- **Dynamic Autonomy:** Modern safe-enhanced DRL controllers continuously adapt to an individual's fluctuating insulin sensitivity, physical exertion, and stress levels without requiring manual recalibration of basal rates by an endocrinologist.




Figure 1: Automated insulin delivery.

3 Screening, Imaging, and Complication Diagnostics

Deep Learning platforms, particularly Convolutional Neural Networks (CNNs), demonstrate diagnostic accuracy matching or exceeding clinical specialists in complication screening:

- **Diabetic Retinopathy (DR):** Autonomous AI systems (such as IDx-DR and EyeArt) utilize deep learning algorithms to evaluate fundus photographs at primary care points without requiring an ophthalmologist on-site (Gulshan et al., 2016; Abràmoff et al., 2018; Yang et al., 2019). Systematic evaluation confirms high diagnostic

accuracy (sensitivity ~93%, specificity ~91%) for autonomous screening in primary care settings

- **Diabetic Foot Ulcers (DFU):** Computer vision and thermographic models detect non-visible inflammatory hotspots (hyperthermic tissue) that precede visible ulceration, enabling preemptive podiatric intervention
- **Diabetic Nephropathy:** Deep learning applied to retinal images can non-invasively detect diabetic kidney disease, offering a scalable screening alternative to traditional urine and blood marker analysis

Methodological Comparison of Key AI Frameworks

Table 1: AI framework Comparison.

Operational Domain	Primary AI / ML Architectures	Core Clinical Deliverable	Key Advantage	Major Technical Limitation
Glucose Forecasting	Time-Series Pre-Clustering, Gradient Boosting, LSTM	30–60 min predictive dysglycemia alerts	High accuracy on temporal time-series patterns	Glucose Forecasting
Glucose Forecasting	Time-Series Pre-Clustering, Gradient Boosting, LSTM	30–60 min predictive dysglycemia alerts	High accuracy on temporal time-series patterns	Glucose Forecasting
Complication Screening	Convolutional Neural Networks (CNN), Vision Transformers	Autonomous DR grading, DFU hotspot detection, Nephropathy detection	Enables scalable point-of-care primary care screening	"Black box" opacity; requires large annotated image sets
Automated Insulin Control	Deep Reinforcement Learning (DRL), Model Predictive Control	Dynamic real-time basal and micro-bolus adjustments	Learns adaptive policies under metabolic variability	Requires strict mathematical safety constraints
Risk Stratification	XGBoost, Random Forests, Decision Trees, Support Vector Machines	T2D onset risk forecasting and hospital readmission scoring	Effective on large tabular health records (EHRs)	Performance drops on incomplete health records

Implementation Challenges and Barriers to Adoption

1. **Model Opacity ("Black Box" Problem):** Deep neural networks perform non-linear transformations that lack human-interpretable reasoning paths. Clinicians remain hesitant to execute aggressive AI-driven insulin dosing adjustments or diagnoses without an interpretable audit trail explaining the output.
2. **Algorithmic Equity and Data Bias:** Many foundational models are trained on homogenous cohorts from high-income urban populations with high technology access. Algorithms trained on these groups may exhibit degraded predictive accuracy when applied to socioeconomically or ethnically diverse populations.
3. **Interoperability and Data Silos:** Medical devices, EHR software, and mobile apps often utilize proprietary data formats. The lack of open interoperability standards hampers unified, real-time AI analytics.
4. **Regulatory, Generative Safety, and Liability Frameworks:** Defining legal accountability remains complex when an autonomous or semi-autonomous algorithmic recommendation results in an adverse clinical outcome (e.g., severe hypoglycemia). Furthermore, emerging generative AI implementations introduce risks of factual inaccuracy ("hallucinations") in clinical decision support.

Future Perspectives

The future of AI in diabetes management is likely to involve increasingly integrated systems rather than isolated algorithms.

Future platforms may combine

CGM + wearable sensors + electronic health records + medication information + dietary data + physical activity + sleep + AI

Such integration could enable dynamic patient profiles that continuously update according to changes in physiology and behavior.

Federated learning may provide an approach for developing models from distributed datasets while reducing the need to centralize sensitive patient information. Explainable AI may make predictions easier for healthcare professionals to interpret. Generative AI may become increasingly useful for education and clinical documentation, although safety and accuracy will remain essential requirements.

Another important direction is the development of AI systems specifically validated in diverse populations. Models should not simply be transferred from one healthcare environment to another without appropriate external validation. Future research should increasingly focus on clinically meaningful endpoints rather than algorithmic accuracy alone. Randomized trials, prospective validation and real-world studies are

required to establish whether AI actually improves glycemic control, reduces complications, improves quality of life or decreases healthcare utilization.

5. CONCLUSION

Artificial Intelligence is transforming diabetes care from periodic, population-wide management into a continuous, predictive, and personalized framework. By optimizing glycemic forecasting, automating insulin delivery, and scaling early screening for complications, AI enhances clinical decision-making. Overcoming implementation barriers regarding model interpretability, dataset diversity, and system interoperability will be crucial for safe and equitable global deployment.

REFERENCES

1. Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018). Pivot trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. *npj Digital Medicine*, 1(1): 39. <https://doi.org/10.1038/s41746-018-0050-6>
2. Alam, M. M., et al. (2024). Machine learning application in personalized diabetes care: A systematic evaluation of clinical outcomes. *Journal of Medical Systems*, 48(1): 12–25.
3. Arcadu, F., Benmansour, F., Maunz, A., Willis, J., Haskova, Z., & Prunotto, M. (2019). Deep learning algorithm predicts diabetic retinopathy progression in individual patients. *npj Digital Medicine*, 2(1): 92. <https://doi.org/10.1038/s41746-019-0172-3>
4. Battelino, T., Danne, T., Bergenstal, R. M., et al. (2019). Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. *Diabetes Care*, 42(8): 1593–1603. <https://doi.org/10.2337/dci19-0028>
5. Broll, S., et al. (2023). Artificial intelligence in closed-loop artificial pancreas systems: Current status and clinical challenges. *Therapeutic Advances in Endocrinology and Metabolism*, 14: 1–18.
6. Contreras, I., & Vehi, J. (2018). Artificial intelligence for diabetes management and decision support: A survey. *Journal of Medical Internet Research*, 20(5): e10775. <https://doi.org/10.2196/10775>
7. Danne, T., Nimri, R., Battelino, T., et al. (2021). International consensus on guidance for automated insulin delivery systems. *Diabetes Care*, 44(8): 1880–1892.
8. Dugas, M., et al. (2024). Predictive machine learning models for early microvascular complications in Type 2 Diabetes using EHR data. *IEEE Journal of Biomedical and Health Informatics*, 28(3): 1420–1431.
9. Frontiers in Endocrinology Editorial. (2025). Artificial intelligence in diabetes care: from predictive analytics to generative AI and implementation challenges. *Frontiers in*

- Endocrinology, 16: 1620132.
<https://doi.org/10.3389/fendo.2025.1620132>
10. Gulshan, V., Peng, L., Coram, M., et al. (2016). Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. *JAMA*, 316(22): 2402–2410.
<https://doi.org/10.1001/jama.2016.17216>
 11. Ting DSW, Cheung CYL, Lim G, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images. *JAMA*. 2017; 318: 2211-2223.
 12. De Fauw J, Ledsam JR, Romera-Paredes B, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. *Nat Med.*, 2018; 24: 1342-1350.
 13. Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. *Nature*. 2017; 542: 115-118.
 14. Saria S, Butte A, Sheikh A. Better medicine through machine learning: what's real, and what's hype? *PLoS Med*. 2018; 15: e1002721.
 15. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. *BMC Med*. 2019; 17: 195.
 16. Wiens J, Saria S, Sendak M, et al. Do no harm: a roadmap for responsible machine learning for health care. *Nat Med*. 2019; 25: 1337-1340.
 17. Chen IY, Pierson E, Rose S, Joshi S, Ferryman K, Ghassemi M. Ethical machine learning in healthcare. *Annu Rev Biomed Data Sci*. 2021; 4: 123-144.
 18. Topol EJ. *Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again*. New York: Basic Books; 2019.